BRCA2 and ovarian cancer: Other common indications include removal of gynecological cancers or risk reduction treatment in women with an inherited increased chance of ovarian cancer as due to gene mutations such as BRCA1, BRCA2 or HNPCC (Rebbeck et al., 2009), or those with a strong family history of ovarian cancer (Parker et al., 2007).